Addus HomeCare (ADUS) Q3 2026 Earnings Call Transcript

Addus HomeCare reported Q3 2026 revenue of $387.7 million, up 7% year over year, adjusted EPS of $1.83 versus $1.56, and adjusted EBITDA of $51.2 million, up 13.5%; adjusted EBITDA margin rose to 13.2% from 12.5%. The company agreed to acquire AccentCare personal care assets for $275 million, adding approximately $280 million in annualized revenue and 13,700 average daily census clients, with closing expected in Q1 2027. Management expects full-year 2026 adjusted EBITDA margin around 13%, while noting acquisition-related service mix could pressure margins next year; bank debt fell by $40 million in the quarter to $24.3 million.

Analysis

ADUS’s key investment tension is growth quality, not growth availability. The pending acquisition can lift reported revenue quickly, but management’s own margin commentary implies initial mix dilution: the acquired personal-care operation is below ADUS’s stated target margin, and synergies are expected to accrue over 12-plus months. The market may therefore over-credit the 19% revenue step-up and underweight the lag between consolidation and earnings conversion. Conversely, the purchase broadens private-pay exposure, which could partially hedge Medicaid rate and policy risk; the scale of that benefit is unverified and should not be assumed from the disclosed mix alone.

Organic signals are improving but not uniformly: home-health admissions have not yet translated into a sustained growth record, while personal-care hours depend on staffing fill rates and census recovery in Texas and Illinois. The caregiver app is an operating lever, but mid-80% authorized-hours fulfillment leaves execution risk as well as upside. Higher DSO appears concentrated in Illinois timing, yet acquisition integration alongside working-capital normalization could temporarily absorb cash.

Over the next 1–3 months, watch closing approvals and Q4 hours/census; over 6–18 months, test whether acquired margins and clinical M&A can offset personal-care mix dilution. The contrarian risk is that a strong EPS quarter masks a slower organic growth base and near-term margin compression. No valuation or current price data is supplied, so conviction should be sized against the operating milestones, not an assumed multiple.

Key Decisions for Investors

• Consider a staged ADUS long rather than chasing the earnings reaction: initiate only at a price offering a reasonable entry versus current valuation, and add after the AccentCare close or evidence of sequential improvement in same-store personal-care hours and census. Without price/valuation data, no numeric entry or target is supportable.
• Treat acquisition accretion as conditional. Track acquired-business margin progression, realized G&A savings, integration costs, and net debt after closing; do not capitalize the revenue addition as equivalent earnings growth.
• Monitor the next two quarters for Texas/Illinois census and authorized-hours fulfillment. A failure to return to positive census or hours growth, or a material miss to the 13% full-year EBITDA-margin outlook, would weaken the long thesis.
• Watch DSO and operating cash conversion through closing. Further collection delays beyond the stated state-payment timing explanation, especially alongside revolver-funded deal costs, would be an early warning that reported earnings are not converting cleanly to cash.